1. Home
  2. SLN vs STRS Comparison

SLN vs STRS Comparison

Compare SLN & STRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • STRS
  • Stock Information
  • Founded
  • SLN 1994
  • STRS 1992
  • Country
  • SLN United Kingdom
  • STRS United States
  • Employees
  • SLN N/A
  • STRS N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • STRS Homebuilding
  • Sector
  • SLN Health Care
  • STRS Real Estate
  • Exchange
  • SLN Nasdaq
  • STRS Nasdaq
  • Market Cap
  • SLN 123.3M
  • STRS 146.8M
  • IPO Year
  • SLN N/A
  • STRS N/A
  • Fundamental
  • Price
  • SLN $3.14
  • STRS $18.33
  • Analyst Decision
  • SLN Buy
  • STRS
  • Analyst Count
  • SLN 5
  • STRS 0
  • Target Price
  • SLN $40.80
  • STRS N/A
  • AVG Volume (30 Days)
  • SLN 292.1K
  • STRS 7.8K
  • Earning Date
  • SLN 05-15-2025
  • STRS 05-13-2025
  • Dividend Yield
  • SLN N/A
  • STRS N/A
  • EPS Growth
  • SLN N/A
  • STRS N/A
  • EPS
  • SLN N/A
  • STRS 0.24
  • Revenue
  • SLN $43,258,000.00
  • STRS $54,183,000.00
  • Revenue This Year
  • SLN N/A
  • STRS N/A
  • Revenue Next Year
  • SLN N/A
  • STRS N/A
  • P/E Ratio
  • SLN N/A
  • STRS $76.38
  • Revenue Growth
  • SLN 36.71
  • STRS 213.74
  • 52 Week Low
  • SLN $1.97
  • STRS $15.50
  • 52 Week High
  • SLN $24.38
  • STRS $30.66
  • Technical
  • Relative Strength Index (RSI)
  • SLN 49.25
  • STRS 50.28
  • Support Level
  • SLN $2.63
  • STRS $17.90
  • Resistance Level
  • SLN $2.95
  • STRS $19.36
  • Average True Range (ATR)
  • SLN 0.43
  • STRS 1.48
  • MACD
  • SLN 0.11
  • STRS 0.07
  • Stochastic Oscillator
  • SLN 72.67
  • STRS 52.31

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations.

Share on Social Networks: